Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cadranel

Showing results (211-220 of 245) with videos related to

Pageof 25
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 17, 2012
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapyE Giroux Leprieur, M Antoine, T Vieira, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Nivolumab-refractory patients with advanced non-small-cell lung cancerA Costantini, V Fallet, J Corny, et al.
The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.
Respiratory Medicine|December 24, 2013
Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologistsV Cottin, J Cadranel, B Crestani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Revue Des Maladies Respiratoires|November 10, 2021
[Rapid outpatient diagnostic pathways for lung cancer: Evaluation after one year]F Millet, M Wislez, V Fallet, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 28, 2022
Why are people still dying of drug-susceptible TB in Paris in the 21<sup>st</sup> century?A-L Beaumont, A Doumbia, N Château, et al.
The European Respiratory Journal|June 23, 2009
Clinical characteristics and prognostic factors of pulmonary MALT lymphomaR Borie, M Wislez, G Thabut, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2015
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targetsV Fallet, R Saffroy, N Girard, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Pageof 25

Showing results (211-220 of 245) with videos related to

Sort By:
Pageof 25
Lung Cancer (Amsterdam, Netherlands)|November 17, 2012
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapyE Giroux Leprieur, M Antoine, T Vieira, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Nivolumab-refractory patients with advanced non-small-cell lung cancerA Costantini, V Fallet, J Corny, et al.
The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.
Respiratory Medicine|December 24, 2013
Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologistsV Cottin, J Cadranel, B Crestani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Revue Des Maladies Respiratoires|November 10, 2021
[Rapid outpatient diagnostic pathways for lung cancer: Evaluation after one year]F Millet, M Wislez, V Fallet, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 28, 2022
Why are people still dying of drug-susceptible TB in Paris in the 21<sup>st</sup> century?A-L Beaumont, A Doumbia, N Château, et al.
The European Respiratory Journal|June 23, 2009
Clinical characteristics and prognostic factors of pulmonary MALT lymphomaR Borie, M Wislez, G Thabut, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2015
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targetsV Fallet, R Saffroy, N Girard, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Pageof 25